InterVenn Biosciences Announces the Publication of Early Detection of Advanced Adenoma and Colorectal Cancer in Gastroenterology

NEWS AND EVENTS

GO BACK
InterVenn Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022

SAN FRANCISCO–(BUSINESS WIRE)–InterVenn Biosciences, the leader in glycoproteomics, today announced Aldo Carrascoso, the company’s CEO and Co-Founder, is scheduled to present at the J.P. Morgan 40th Annual Healthcare Conference on January 12, 2022, from 3:00 – 3:25 pm EST. Mr. Carrascoso will provide a company overview of InterVenn and its first-of-its-kind glycoproteomics solutions.

Following the company presentation, management will participate in a virtual breakout session. InterVenn management will also participate in one-on-one meetings with investors, analysts, and other interested parties during the conference.

 

Contact
Anthony Petrucci
Bioscribe
anthony@bioscribe.com

Get in touch